Yan Sun

Yan Sun

Auto-generated profile, based on publicly available information

Yan Sun

Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu, China; Key Laboratory of Integrative Biomedicine for Brain Diseases, School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R China; National Famous Chinese Medicine Expert Inheritance Studio (Meng Jingchun), Nanjing University of Chinese Medicine, School of Chinese Medicine, Nanjing, 210023, P. R China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in British Journal of Pharmacology
Verified
Journal Article
Closed access
HZHailou Zhang
Hailou Zhang
YSYan Sun
Yan Sun
SYSuk-yu Yau
Suk-yu Yau
YZYanmeng Zhou
Yanmeng Zhou
XSXinxin Song
Xinxin Song
GCGang Chen
Gang Chen

3 February 2022 in Journal of Functional Foods
Verified
Journal Article
Open access
XDXianling Dai
Xianling Dai
QKQin Kuang
Qin Kuang
YSYan Sun
Yan Sun
MXMinxuan Xu
Minxuan Xu
LZLiancai Zhu
Liancai Zhu
BWBochu Wang
Bochu Wang

24 February 2023 in Pharmaceutical Biology
Verified
Journal Article
Open access
RLRuiyi Liu
Ruiyi Liu
YSYan Sun
Yan Sun
DDDong Di
Dong Di
XZXiyuan Zhang
Xiyuan Zhang
BZBoran Zhu
Boran Zhu
HWHaoxin Wu
Haoxin Wu
Previously, we found Alisma orientalis beverage (AOB), a classic traditional Chinese medicine (TCM) formulation, had the potential effect of treating atherosclerosis (AS). The underlying mechanism ...

7 July 2022 in Hepatology
Verified
Journal Article
Closed access
MXMinxuan Xu
Minxuan Xu
JTJun Tan
Jun Tan
CGChen‐Xu Ge
Chen‐Xu Ge
WDWei Dong
Wei Dong
LZLi‐Ting Zhang
Li‐Ting Zhang
BWBo‐Chu Wang
Bo‐Chu Wang
Background & Aims: As a global health threat, NASH has been confirmed to be a chronic progressive liver disease that is strongly associated with obesity. However, no approved drugs or efficient therapeutic strategies are valid, mainly because its complicated pathological processes is underestimated. Approach & Results: We identified the RING‐type E3 ubiquitin transferase‐tripartite motif‐containing protein 31 (TRIM31), a member of the E3 ubiquitin ligases family, as an efficient endogenous inhibitor of transforming growth factor‐beta‐activated kinase 1 (mitogen‐activated protein kinase kinase kinase 7; MAP3K7), and we further confirmed that TRIM31 is an MAP3K7‐interacting protein and promotes MAP3K7 degradation by enhancing ubiquitination of K48 linkage in hepatocytes. Hepatocyte‐specific Trim31 deletion blocks hepatic metabolism homeostasis, concomitant with glucose metabolic syndrome, lipid accumulation, up‐regulated inflammation, and dramatically facilitates NASH progression. Inversely, transgenic overexpression, lentivirus, or adeno‐associated virus‐mediated Trim31 gene therapy restrain NASH in three dietary mice models. Mechanistically, in response to metabolic insults, TRIM31 interacts with MAP3K7 and conjugates K48‐linked ubiquitination chains to promote MAP3K7 degradation, thus blocking MAP3K7 abundance and its downstream signaling cascade activation in hepatocytes. Conclusions: TRIM31 may serve as a promising therapeutic target for NASH treatment and associated metabolic disorders.

11 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JLJing Liu
Jing Liu
SZShihan Zhou
Shihan Zhou
YWYanqing Wang
Yanqing Wang
JLJinling Liu
Jinling Liu
SSSuPing Sun
SuPing Sun
HWHaoxin Wu
Haoxin Wu

11 March 2024 in Phytomedicine
Verified
Journal Article
Closed access
YSYan Sun
Yan Sun
HZHailou Zhang
Hailou Zhang
RLRuiyi Liu
Ruiyi Liu
RHRumin Huang
Rumin Huang
ZGZiwei Gao
Ziwei Gao
LWLei Wu
Lei Wu